NCT06069518 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Almalki MH, Altuwaijri MA, Almehthel MS, Sirrs SM, Singh RS
Subcutaneous versus intraperitoneal insulin for patients with diabetes mellitus on continuous ambulatory peritoneal dialysis: meta-analysis of non-randomized clinical trials. Clin Invest Med. 2012 Jun 1;35(3):E132-43. doi: 10.25011/cim.v35i3.16589.
Bomholt T, Kofod D, Norgaard K, Rossing P, Feldt-Rasmussen B, Hornum M
Can the Use of Continuous Glucose Monitoring Improve Glycemic Control in Patients with Type 1 and 2 Diabetes Receiving Dialysis? Nephron. 2023;147(2):91-96. doi: 10.1159/000525676. Epub 2022 Jul 13.
Galindo RJ, Beck RW, Scioscia MF, Umpierrez GE, Tuttle KR
Glycemic Monitoring and Management in Advanced Chronic Kidney Disease. Endocr Rev. 2020 Oct 1;41(5):756-74. doi: 10.1210/endrev/bnaa017.
Ng JKC, Ling J, Luk AOY, Lau ESH, Ma RCW, Li PKT, Szeto CC, Chan JCN, Chow E
Evaluation of a Fourth-Generation Subcutaneous Real-Time Continuous Glucose Monitor (CGM) in Individuals With Diabetes on Peritoneal Dialysis. Diabetes Care. 2023 Jun 1;46(6):1191-1195. doi: 10.2337/dc22-2348.
Selby NM, Fonseca S, Hulme L, Fluck RJ, Taal MW, McIntyre CW
Hypertonic glucose-based peritoneal dialysate is associated with higher blood pressure and adverse haemodynamics as compared with icodextrin. Nephrol Dial Transplant. 2005 Sep;20(9):1848-53. doi: 10.1093/ndt/gfh946. Epub 2005 Jun 21.

Continuous Glucose Monitoring as a Strategy to Optimize Metabolic Control in Patients With Diabetes on Peritoneal Dialysis Therapy Entitled to the IMSS

Details for clinical trial NCT06069518

Clinical trial NCT06069518 - References